EGFR and lung cancer: In patients with EGFR-mut lung cancer, TMB has been shown to be associated with a poor response to tyrosine kinase inhibitors [109], and a meta-analysis of clinical trial data reported that patients with EGRF-mut tumors demonstrate a poor therapeutic response to immunotherapies [110].